Skip to main content
. 2017 Aug 7;8(44):76797–76806. doi: 10.18632/oncotarget.20012

Figure 1.

Figure 1

(A) Methylation level of Alu: The median methylation level of Alu was 46.15% (IQR, 36.57%–54.00%) and 60.85% (IQR, 57.23%–65.68%) in glioma patients and healthy controls. (B) Methylation level of MGMT: The median methylation level of MGMT was 64.65% (IQR, 54.87%–74.37%) and 38.30% (IQR, 34.13%–45.45%) in glioma patients and healthy controls. (C) Methylation level of RASSF1A: The median methylation level of RASSF1A was 15.50% (IQR, 5.85%–24.70%) and 11.40% (IQR, 6.78%–20.60%) in glioma patients and healthy controls. (D) Methylation level of P16: The median methylation level of P16 was 31.35% (IQR, 22.58%–36.93%) and 26.65% (IQR, 17.15%–36.05%) in glioma patients and healthy controls.